The outlook of companies tied to the drug's legacy presents a intricate investment landscape. While the initial boom generated substantial gains, generic alternatives have significantly eroded market share . https://pharma050931.blogminds.com/copyright-s-flagship-product-and-big-pharma-a-speculative-venture-38648363